- Previous Close
124.60 - Open
126.80 - Bid 121.00 x --
- Ask 121.45 x --
- Day's Range
120.00 - 126.80 - 52 Week Range
71.00 - 144.60 - Volume
7,169 - Avg. Volume
6,265 - Market Cap (intraday)
2.546B - Beta (5Y Monthly) 1.04
- PE Ratio (TTM)
12.23 - EPS (TTM)
9.89 - Earnings Date Feb 11, 2025 - Feb 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Alpa Laboratories Limited engages in the manufacture and sale of pharmaceutical finished dosage forms in India. The company offers ethical, generic, and over the counter pharmaceutical products in various finished dosage forms, including injections, tablets, capsules, eye and ear drops, creams, gels, and ointments for human and veterinary use. It also provides drugs in various categories, such as anti-infectives comprising antibacterial, antibiotics, antifungals, antiprotozoals, and antivirals; analgesics; anti-inflammatory drugs; cough and cold drugs; cardiovascular drugs; anti-diabetics; nutritional supplements; psychotropic drugs; and skin care preparations, as well as ear and eye care preparations. The company sells its products through distributors, retail chemists, retail pharmacy stores, and hospitals. It also exports its products to South and Central America, Africa, and Asia, Russia, Ukraine, Kazakhstan, and internationally. The company was founded in 1967 and is based in Indore, India.
www.alpalabs.in410
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: ALPA.BO
View MorePerformance Overview: ALPA.BO
Trailing total returns as of 1/17/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALPA.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALPA.BO
View MoreValuation Measures
Market Cap
2.55B
Enterprise Value
1.47B
Trailing P/E
12.26
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.65
Price/Book (mrq)
1.55
Enterprise Value/Revenue
1.52
Enterprise Value/EBITDA
5.02
Financial Highlights
Profitability and Income Statement
Profit Margin
14.94%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
1.09B
Net Income Avi to Common (ttm)
162.42M
Diluted EPS (ttm)
9.89
Balance Sheet and Cash Flow
Total Cash (mrq)
928.54M
Total Debt/Equity (mrq)
3.45%
Levered Free Cash Flow (ttm)
--